Abstract
β 3-adrenoceptors have been described through both molecular and pharmacological studies. In this context, it has been characterized the β 3-adrenoceptors agonist activity of a new compound (Trecadrine ®), and evaluated whether it exhibits additional activity at β 1 and β 2- adrenoceptor subtypes. In addition, it has been tested its potential anti-diabetic properties in a model of alloxan-induced diabetes in rats. Our data show that Trecadrine ® induces oesophageal muscularis mucosae relaxation, indicating a putative action on β 3-adrenoceptors. In the absence of β 3-adrenoceptors antagonists, assays with β 1 and β 2-adrenergic antagonists reveal a quite remarkable selectivity for β 3-adrenoceptors. Furthermore, it has been suggested that this molecule has hypoglycaemic and lipomobilizing effects, although hypoglycaemia was not related to an increase in insulin secretion in diabetic rats. It is concluded that Trecadrine ® mainly acts through β 3-adrenoceptors, and it may constitute a potential drug in the treatment of diabetes.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
